A machine learning model that uses DNA methylation patterns may help identify the origin of cancers of unknown primary
medicalxpress - A machine learning model analyzing CpG-based DNA methylation accurately predicted the origin of many different cancer types in patients with cancers of unknown primary (CUP), according to research presented at the American Association for Cancer Research …
AI Summary: A machine‑learning model trained on DNA methylation signatures can assign tissue‑of‑origin for cancers of unknown primary with promising accuracy. The approach could speed diagnosis, guide therapy choices and reduce reliance on invasive tests—handy when a tumor refuses to tell doctors where it came from.
- ctDNA and AI for treatment monitoring and early detection (3)
- Liquid biopsies and extracellular vesicles for early cancer detection (4)
- Methylation-based ML to identify cancers' tissue of origin (3)
- All Other Stories
ctDNA and AI for treatment monitoring and early detection
Liquid biopsies and extracellular vesicles for early cancer detection
Methylation-based ML to identify cancers' tissue of origin
All Other Stories
A deep learning pathomics platform may help predict response to immunotherapy in lung cancer patients
medicalxpress - A biology-guided artificial intelligence model applied to routine pathology slides accurately predicted outcomes and response to immunotherapy in patients with metastatic non-small cell lung cancer (NSCLC), according to a study presented at the American A…
AI Summary: Researchers developed a deep‑learning pathomics platform that analyzes routine histology to predict which lung cancer patients are likely to respond to immunotherapy. By extracting subtle morphological patterns invisible to the human eye, the tool promises to refine treatment selection and spare nonresponders unnecessary toxicity—assuming clinicians trust an algorithm more than their gut.
- AI pathomics flags immunotherapy responders in lung cancer (4)
- Challenges deploying AI in lung cancer diagnosis and care (3)
- Evolving lung cancer immunotherapy trials and biomarker debates (4)
- All Other Stories